Sign In
Buy AVXL
$2.65
-0.140 (-5.03%)
At Close: Jun 03, 2026
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
07:30am, Thursday, 18'th Dec 2025
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
04:05pm, Friday, 12'th Dec 2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
10:00am, Thursday, 11'th Dec 2025
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
09:50am, Wednesday, 10'th Dec 2025
LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Scien
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
07:39pm, Wednesday, 03'rd Dec 2025
LOS ANGELES--(BUSINESS WIRE)---- $AVXL--AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm.
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL)
10:36am, Tuesday, 02'nd Dec 2025
Anavex Life Sciences (AVXL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
07:30am, Wednesday, 26'th Nov 2025
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript
11:53am, Tuesday, 25'th Nov 2025
Anavex Life Sciences Corp. ( AVXL ) Q4 2025 Earnings Call November 25, 2025 8:30 AM EST Company Participants Clint Tomlinson - VP of Corporate Christopher Missling - President, CEO, Secretary & Direct
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
07:30am, Tuesday, 25'th Nov 2025
Company to host a webcast t oday at 8:30 a.m. Eastern Time
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
07:30am, Wednesday, 19'th Nov 2025
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
07:56pm, Tuesday, 18'th Nov 2025
NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
07:30am, Tuesday, 18'th Nov 2025
Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
07:30am, Friday, 14'th Nov 2025
Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144
Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” Presentation title: “Advancing Alzheimer's Disease Care: Convenience f
